SecBot SecBot
SC 13G/A ·Filed Nov 10, 2026

PPBT

PURPLE BIOTECH LTD.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6d 9h ago SEC0001213900-26-118162
Passive stake amendment
Actionable Insight • Neutral

Monitor for any future conversion of the Intracoastal warrant or changes in the blocker provision, which could signal a shift from passive to active engagement. The stake percentage has remained at 9.99% across recent filings, indicating a stable passive position.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.49
T+0 close · Nov 10, 2026 · via day close
Latest settled
+4.70%
T+1 · $1.56
Vs SPY
+5.05%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $1.49entry
  2. T+1 · 5d ago +4.70%α +5.05% · $1.56
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Intracoastal Capital LLC and its principals filed an amended Schedule 13G disclosing beneficial ownership of 206,941,858 ordinary shares of Purple Biotech Ltd. (9.99% of outstanding shares) as of September 30, 2026, all of which are issuable upon exercise of a warrant. The filing is a routine passive stake amendment with no change in reported ownership percentage from prior filings.

Key Financial Metrics

Stake
9.99%
Investor
Intracoastal Capital LLC
Investor Type
hedge fund

Key Facts

  • Intracoastal Capital LLC and its principals Mitchell P. Kopin and Daniel B. Asher filed an amended Schedule 13G on November 10, 2026.
  • As of September 30, 2026, the Reporting Persons beneficially own 206,941,858 ordinary shares (9.99% of outstanding shares), all issuable upon exercise of a warrant.
  • The warrant contains a blocker provision limiting beneficial ownership to 9.99%; without it, the warrant would cover 400,000,000 ordinary shares.
  • The issuer had 1,864,548,218 ordinary shares outstanding as of May 20, 2026.
  • The filing is a passive investor disclosure under Rule 13d-1(c) with no indication of activist intent.

Financial Impact

No financial impact; passive stake amendment with no change in reported ownership percentage.

Risk Factors

  • The warrant blocker provision limits exercise to 9.99%, but any amendment or waiver could lead to significant dilution.
  • The company's market cap is only $2M, making the stake highly concentrated and potentially volatile.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001213900-26-118162
Document: 0001213900-26-118162-index.html0001213900-26-118162
Document: 0001213900-26-118162.txt0001213900-26-118162

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026